<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00192179</url>
  </required_header>
  <id_info>
    <org_study_id>D153-P526</org_study_id>
    <nct_id>NCT00192179</nct_id>
  </id_info>
  <brief_title>A Phase II, Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, CAIV-T in Healthy Children and Adolescents Ages 6 to Less Than 18 Years.</brief_title>
  <acronym>FluMist</acronym>
  <official_title>A Phase II, Prospective, Randomized, Double-Blind, Placebo, Controlled Trial, to Assess the Safety and Tolerability of Influenza Virus Vaccine, Trivalent, Types A &amp; B Live Cold-Adapted Liquid Formulation (CAIV-T) in Healthy Children and Adolescents Ages 6 to Less Than 18 Years.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A safety study to compare, over a 7 day period, the fever rates following one dose of either
      Influenza Virus Vaccine or placebo administered outside the influenza season to healthy
      children and adolescents aged 6 to less than 18 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a prospective, randomized, double-blind, placebo-controlled, study. Subjects were
      randomized to receive either CAIV-T or Placebo. All subjects were healthy children and
      adolescents aged at least 6 years of age and less than 18 years of age at the time of
      enrollment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">July 2003</completion_date>
  <primary_completion_date type="Actual">July 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with fever greater than or equal to 39.1C oral</measure>
    <time_frame>Days 0-7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with any reactogenicity</measure>
    <time_frame>Day 0-7</time_frame>
    <description>Following vaccination the following reactions were reported daily: runny nose/nasal congestion, sore throat, cough, vomiting, decreased activity level, decreased appetite, irritability, abdominal pain together with oral temperature were referred to as prompted systemic reactions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with any adverse events</measure>
    <time_frame>Days 0-7</time_frame>
    <description>Adverse events were defined as any untoward, undesired or unexpected clinical event in the form of signs, symptoms, disease or laboratory or physiological observations that occurred in a temporal relationship to the use of a WVR product, regardless of causal relationship.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with any serious adverse events</measure>
    <time_frame>Days 0-21</time_frame>
    <description>A Serious AE was an AE that occurred after any dose that: resulted in death, regardless of cause; was life-threatening; required in-patient hospitalization or prolonged an existing hospitalization; resulted in a persistent or significant disability or incapacity; resulted in cancer; resulted in a congenital anomaly or birth defect (in the offspring of a vaccine recipient, where applicable).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>CAIV-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cold-adapted influenza vaccine trivalent (CAIV-T)</intervention_name>
    <description>The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 ml into each nostril). Each dose of CAIV-T used in this study contained approximately 10^7+/-0.5 fluorescent focus units (FFU) (equivalent to 10^7+/-0.5 TCID50) of each of the following three influenza virus strains: Influenza Cold Adapted Virus Type H1N1, strain A/New Caledonia/20/99; Influenza Cold Adapted Virus Type H3N2, strain A/ Panama/2007/99; Influenza Cold Adapted Virus Type B, strain B/Hong Kong/ 330/01.</description>
    <arm_group_label>CAIV-T</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo consisted of physiologic normal saline.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  who are aged 6 to less than 18 years at the time of enrolment

          -  who, if female and is of child bearing potential is using reliable method of hormonal
             and/or non-hormonal contraception (which includes cervical cap, diaphragm, condoms,
             with spermicide or IUD) during sexual intercourse throughout the entire study period;
             has provided a negative pregnancy test (with detection limit of less than or equal to
             25mL/ml) no more than 24 hours prior to the study vaccine administration and agreed to
             avoid pregnancy during participation in the study.

        N.B.lactating females are excluded from the study.

          -  who are in good health as determined by medical history, physical examination and
             clinical judgement

          -  whose parent(s)/legal guardian(s) have provided written informed consent after the
             nature of the study has been explained

          -  who, along with their parent(s)/legal guardian(s) will be available until completion
             of the study

          -  whose parent(s)/legal guardian(s), can be reached by study staff for the post
             vaccination contacts(telephone, clinic or home visit)

        Exclusion Criteria:

          -  who along with their parent(s)/legal guardian(s) are perceived to be unavailable or
             difficult to contact for evaluation or study visits during the study period

          -  with any serious chronic disease (e.g. with signs of cardiac or renal failure or
             severe malnutrition) including progressive neurological disease

          -  with Down's syndrome or other known cytogenetic disorders

          -  with a known or suspected disease of the immune system or those receiving
             immunosuppressive therapy, including systemic corticosteroids; or cytotoxic agents

          -  who received any blood products, including immunoglobulin, in the period from six
             months prior to vaccination through to the conclusion of the study

          -  have an immunosuppressed or an immunocompromised individual living in the same
             household

          -  with a documented history of hypersensitivity to egg or egg protein or any other
             components of CAIV-T or placebo

          -  who have a history of Guillain-Barre Syndrome (GBS)

          -  for whom there is intent to administer any other investigational vaccine or agent from
             one month prior to enrollment through to the conclusion of the study

          -  who, in the two weeks prior to entry into the study, received a dose of influenza
             treatment (commercial or investigational)

          -  who received aspirin (acetylsalicylic acid) or aspirin-containing products in the two
             weeks prior to enrollment or for which use is anticipated during the study

          -  who, at anytime prior to study enrollment, received any influenza vaccine (commercial
             or investigational)

          -  with asthma requiring regular medical follow up or hospitalization during the
             preceding year

          -  with any medical conditions that in the opinion of the investigator might interfere
             with interpretation of the study results

          -  Note: Pregnancy in any person who has regular contact with the subjects is not a
             contraindication to enrollment or ongoing participation of the subject in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raburn Mallory, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Catholic University Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zamenhoflaan 12</name>
      <address>
        <city>Schoten</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universiteit Antwerpen</name>
      <address>
        <city>Wilrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddzial Dzieciecy Szpitala Powiatowete im</name>
      <address>
        <city>Trzebnica</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Gables Medicentre</name>
      <address>
        <city>Coventry</city>
        <zip>CV 6 4DD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Townhead Surgery</name>
      <address>
        <city>Irvine, Ayshire</city>
        <zip>KA 12 OAY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>February 29, 2012</last_update_submitted>
  <last_update_submitted_qc>February 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2012</last_update_posted>
  <responsible_party>
    <name_title>Raburn Mallory, MD/ Sr Dir Clinical Development</name_title>
    <organization>MedImmune</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

